person · Reporting owner

High Katherine A

Disclosed activity across 3 companies

Tapewire entity: 39853
SEC CIK: 0001631248

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRISPR Therapeutics AGCRSP · Entity 3852	Director	June 05, 2026	June 09, 2026
INCYTE CORPINCY · Entity 3182	Director	June 08, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date June 05, 2026 · Filed June 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05	Direct	13,000	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

INCYTE CORP

Report date June 08, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	14,983	Reported balance After 2026-06-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 14,983 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07	Direct	6,111	Reported balance After 2026-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Filing footnotes · ownership attribution and instrument terms

F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Spark Therapeutics, Inc.

Report date December 17, 2019 · Filed December 17, 2019

Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-12-17 transaction · row 1 1 source row Row 1 · 2019-12-17 · Other · Disposed 278,834 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.73 · Expires 2029-01-15	Direct	Reported balance After 2019-12-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-17 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.55 · Expires 2028-01-17	Direct	Reported balance After 2019-12-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-12-17 · Disposition to issuer · Disposed 23,625 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.17 · Expires 2027-01-17	Direct	Reported balance After 2019-12-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-12-17 · Disposition to issuer · Disposed 15,750 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.44 · Expires 2026-01-04	Direct	Reported balance After 2019-12-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-12-17 · Disposition to issuer · Disposed 13,750 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-12-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-12-17 · Disposition to issuer · Disposed 21,250 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 18, 2019 Filed Jan 23, 2019 22:15 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionRestricted Stock Units · Derivative	2,250	$0.00	$0.00	Disclosure SEC source: 0001609351-19-000025 · wf-form4_154828171338855.xml · derivative · entry 5 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: On January 18, 2017, the reporting person was granted 9,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: On January 18, 2017, the reporting person was granted 9,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 18, 2019 Filed Jan 23, 2019 22:15 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Tax withholdingCommon Stock	683	$45.08	$30,789.64	Disclosure SEC source: 0001609351-19-000025 · wf-form4_154828171338855.xml · nonDerivative · entry 4 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,468 Read SEC document
January 18, 2019 Filed Jan 23, 2019 22:15 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	2,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001609351-19-000025 · wf-form4_154828171338855.xml · nonDerivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document
January 18, 2019 Filed Jan 23, 2019 22:15 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Tax withholdingCommon Stock	808	$45.08	$36,424.64	Disclosure SEC source: 0001609351-19-000025 · wf-form4_154828171338855.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,901 Read SEC document
January 18, 2019 Filed Jan 23, 2019 22:15 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	2,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001609351-19-000025 · wf-form4_154828171338855.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document
January 15, 2019 Filed Jan 18, 2019 02:39 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	10,000	$0.00	$0.00	Disclosure SEC source: 0001609351-19-000010 · wf-form4_154777912840997.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic's Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 15, 2019 Filed Jan 18, 2019 02:39 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantEmployee Stock Option (right to buy) · Derivative	35,000	$0.00 Strike: $42.73	$0.00	Disclosure SEC source: 0001609351-19-000010 · wf-form4_154777912840997.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-15 F1 · derivative.exercise_date: 25% vests January 15, 2020 and the remainder vests in equal annual installments over the following three years. Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:04 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionRestricted Stock Units · Derivative	2,250	$0.00	$0.00	Disclosure SEC source: 0001609351-18-000012 · wf-form4_151666586678662.xml · derivative · entry 5 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F5 · derivative.exercise_date: On January 18, 2017, the reporting person was granted 9,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F5 · derivative.expiration_date: On January 18, 2017, the reporting person was granted 9,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:04 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	9,000	$0.00	$0.00	Disclosure SEC source: 0001609351-18-000012 · wf-form4_151666586678662.xml · derivative · entry 4 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:04 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantEmployee Stock Option (right to buy) · Derivative	31,500	$0.00 Strike: $50.55	$0.00	Disclosure SEC source: 0001609351-18-000012 · wf-form4_151666586678662.xml · derivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2028-01-17 F2 · derivative.exercise_date: 25% vests January 18, 2019 and the remainder vests in equal annual installments over the following three years. Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:04 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Tax withholdingCommon Stock	791	$50.55	$39,985.05	Disclosure SEC source: 0001609351-18-000012 · wf-form4_151666586678662.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,459 Read SEC document
January 18, 2018 Filed Jan 23, 2018 00:04 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	2,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001609351-18-000012 · wf-form4_151666586678662.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics common stock. Read SEC document
November 28, 2017 Filed Nov 29, 2017 22:08 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000125 · wf-form4_151199331155712.xml · derivative · entry 4 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,249 Underlying: Common Stock · 5,000 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
November 28, 2017 Filed Nov 29, 2017 22:08 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	1,500	$72.27	$108,405.00	Disclosure SEC source: 0001609351-17-000125 · wf-form4_151199331155712.xml · nonDerivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. Read SEC document
November 28, 2017 Filed Nov 29, 2017 22:08 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	3,500	$70.91	$248,185.00	Disclosure SEC source: 0001609351-17-000125 · wf-form4_151199331155712.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,500 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.54 to $71.25, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
November 28, 2017 Filed Nov 29, 2017 22:08 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	5,000	$3.45	$17,250.00	Disclosure SEC source: 0001609351-17-000125 · wf-form4_151199331155712.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 31, 2017 Filed Nov 6, 2017 14:16 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000110 · wf-form4_150997776715774.xml · derivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,249 Underlying: Common Stock · 5,000 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
October 31, 2017 Filed Nov 6, 2017 14:16 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	5,000	$83.30	$416,500.00	Disclosure SEC source: 0001609351-17-000110 · wf-form4_150997776715774.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.08 to $83.75, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
October 31, 2017 Filed Nov 6, 2017 14:16 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	5,000	$3.45	$17,250.00	Disclosure SEC source: 0001609351-17-000110 · wf-form4_150997776715774.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 26, 2017 Filed Sep 28, 2017 21:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000107 · wf-form4_150663456754120.xml · derivative · entry 4 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,249 Underlying: Common Stock · 5,000 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
September 26, 2017 Filed Sep 28, 2017 21:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	3,519	$86.67	$304,991.73	Disclosure SEC source: 0001609351-17-000107 · wf-form4_150663456754120.xml · nonDerivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.50 to $87.00, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document
September 26, 2017 Filed Sep 28, 2017 21:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	1,481	$84.95	$125,810.95	Disclosure SEC source: 0001609351-17-000107 · wf-form4_150663456754120.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,519 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.71 to $85.67, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
September 26, 2017 Filed Sep 28, 2017 21:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	5,000	$3.45	$17,250.00	Disclosure SEC source: 0001609351-17-000107 · wf-form4_150663456754120.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 29, 2017 Filed Sep 1, 2017 20:40 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000098 · wf-form4_150429842330875.xml · derivative · entry 4 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,249 Underlying: Common Stock · 10,000 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
August 29, 2017 Filed Sep 1, 2017 20:40 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	1,839	$81.16	$149,253.24	Disclosure SEC source: 0001609351-17-000098 · wf-form4_150429842330875.xml · nonDerivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.94 to $81.45, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document
August 29, 2017 Filed Sep 1, 2017 20:40 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	8,161	$80.05	$653,288.05	Disclosure SEC source: 0001609351-17-000098 · wf-form4_150429842330875.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,839 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.89 to $80.88, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
August 29, 2017 Filed Sep 1, 2017 20:40 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	10,000	$3.45	$34,500.00	Disclosure SEC source: 0001609351-17-000098 · wf-form4_150429842330875.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000080 · wf-form4_150110005560658.xml · derivative · entry 4 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,249 Underlying: Common Stock · 10,000 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	1,500	$74.11	$111,165.00	Disclosure SEC source: 0001609351-17-000080 · wf-form4_150110005560658.xml · nonDerivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	8,500	$72.25	$614,125.00	Disclosure SEC source: 0001609351-17-000080 · wf-form4_150110005560658.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,500 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.85, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:14 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	10,000	$3.45	$34,500.00	Disclosure SEC source: 0001609351-17-000080 · wf-form4_150110005560658.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 27, 2017 Filed Jun 29, 2017 20:29 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000067 · wf-form4_149876816916250.xml · derivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,249 Underlying: Common Stock · 10,000 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
June 27, 2017 Filed Jun 29, 2017 20:29 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	10,000	$60.96	$609,600.00	Disclosure SEC source: 0001609351-17-000067 · wf-form4_149876816916250.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.80 to $61.12, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
June 27, 2017 Filed Jun 29, 2017 20:29 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	10,000	$3.45	$34,500.00	Disclosure SEC source: 0001609351-17-000067 · wf-form4_149876816916250.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 19, 2017 Filed Jun 21, 2017 20:44 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000061 · wf-form4_149807783601601.xml · derivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,249 Underlying: Common Stock · 10,000 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
June 19, 2017 Filed Jun 21, 2017 20:44 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	10,000	$60.00	$600,000.00	Disclosure SEC source: 0001609351-17-000061 · wf-form4_149807783601601.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. Read SEC document
June 19, 2017 Filed Jun 21, 2017 20:44 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	10,000	$3.45	$34,500.00	Disclosure SEC source: 0001609351-17-000061 · wf-form4_149807783601601.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 28, 2017 Filed May 2, 2017 20:41 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000031 · wf-form4_149375765979712.xml · derivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,249 Underlying: Common Stock · 15,000 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
April 28, 2017 Filed May 2, 2017 20:41 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	15,000	$58.06	$870,900.00	Disclosure SEC source: 0001609351-17-000031 · wf-form4_149375765979712.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.80 to $58.32, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
April 28, 2017 Filed May 2, 2017 20:41 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	15,000	$3.45	$51,750.00	Disclosure SEC source: 0001609351-17-000031 · wf-form4_149375765979712.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 25, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	12,940	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000029 · wf-form4_149324329172915.xml · derivative · entry 7 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,249 Underlying: Common Stock · 12,940 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
April 25, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	110	$56.01	$6,161.10	Disclosure SEC source: 0001609351-17-000029 · wf-form4_149324329172915.xml · nonDerivative · entry 5 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · shares: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.01, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. Read SEC document
April 25, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	12,830	$55.38	$710,525.40	Disclosure SEC source: 0001609351-17-000029 · wf-form4_149324329172915.xml · nonDerivative · entry 4 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,110 F1 · shares: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.96, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document
April 25, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	12,940	$3.45	$44,643.00	Disclosure SEC source: 0001609351-17-000029 · wf-form4_149324329172915.xml · nonDerivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 24, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	2,060	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001609351-17-000029 · wf-form4_149324329172915.xml · derivative · entry 6 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,189 Underlying: Common Stock · 2,060 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document
April 24, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	2,060	$55.01	$113,320.60	Disclosure SEC source: 0001609351-17-000029 · wf-form4_149324329172915.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · shares: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.02, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
April 24, 2017 Filed Apr 26, 2017 21:48 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	2,060	$3.45	$7,107.00	Disclosure SEC source: 0001609351-17-000029 · wf-form4_149324329172915.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 18, 2017 Filed Jan 20, 2017 21:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantRestricted Stock Units · Derivative	9,000	$0.00	$0.00	Disclosure SEC source: 0001609351-17-000011 · wf-form4_148494634366185.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document
January 18, 2017 Filed Jan 20, 2017 21:05 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	GrantEmployee Stock Option (right to buy) · Derivative	31,500	$0.00 Strike: $56.17	$0.00	Disclosure SEC source: 0001609351-17-000011 · wf-form4_148494634366185.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2027-01-17 F1 · derivative.exercise_date: 25% vests January 18, 2018 and the remainder vests in equal annual installments over the following three years. Read SEC document
November 14, 2016 Filed Nov 16, 2016 23:09 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	SaleCommon Stock	10,000	$60.30	$603,000.00	Disclosure SEC source: 0001609351-16-000109 · wf-form4_147933777931827.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 F1 · date: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.90, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.